top of page
The Professional Network for Healthcare Experts
Merck licenses SciBrunch KRAS G12D inhibitor in deal worth up to $2.13bn
Merck has secured exclusive worldwide rights to SciBrunch Therapeutics' preclinical KRAS G12D inhibitor SPR2015 in an oncology licensing transaction worth up to $2.13 billion.
nuaxia
Sep 292 min read
FDA approves Lyrfigtu for previously treated FGFR2-altered cholangiocarcinoma
The FDA has approved Lyrfigtu for adults with previously treated FGFR2-altered cholangiocarcinoma, adding a new targeted therapy for this molecularly defined group of bile duct cancers.
nuaxia
Sep 241 min read
FDA approves first-in-class targeted therapy daraxonrasib for metastatic pancreatic cancer
The approval introduces the first RAS(ON) inhibitor for previously treated metastatic pancreatic ductal adenocarcinoma with a KRAS G12X mutation, establishing a new biomarker-directed option for one of the hardest-to-treat cancers.
nuaxia
Aug 272 min read
bottom of page